New device can sniff out bladder cancer

Image
Press Trust of India London
Last Updated : Jul 09 2013 | 3:25 PM IST
Scientists have developed a new device that can 'smell' bladder cancer from certain odours in the urine and give an accurate diagnosis within 30 minutes.
Researchers from the University of Liverpool and University of the West of England, (UWE Bristol), built the device, called ODOREADER that contains a sensor which responds to chemicals in gas emitted from urine.
The device, constructed in the laboratories at UWE Bristol's Institute of Biosensor Technology, analyses this gas and produces a 'profile' of the chemicals in urine that can be read by scientists to diagnose the presence of cancer cells in the bladder.
There are currently no reliable biomarkers to screen patients for bladder cancer in the same way that there are for breast and cervical cancers.
Previous research has suggested that a particular odour in the urine could be detected by dogs trained to recognise the scent, indicating that methods of diagnoses could be based on the smell of certain gases.
The device works by inserting a bottle containing the urine sample into the device. About 30 minutes later the ODOREADER is capable of showing the diagnosis on the computer screen if the sample derives from a patient with bladder cancer.
"It is thought that dogs can smell cancer, but this is obviously not a practical way for hospitals to diagnose the disease," said Professor Norman Ratcliffe, from the Institute of Biosensor Technology at UWE Bristol, said.
"Taking this principle, however, we have developed a device that can give us a profile of the odour in urine. It reads the gases that chemicals in the urine can give off when the sample is heated," Ratcliffe said.
"We looked at 98 samples of urine to develop the device, and tested it on 24 patient samples known to have cancer and 74 samples that have urological symptoms, but no cancer. The device correctly assigned 100 per cent of cancer patients," said Professor Chris Probert, from the University of Liverpool's Institute of Translational Medicine.
"Bladder cancer is said to be the most expensive cancer to treat, due to repeated scopes to inspect the development of the cancer cells in the bladder. ODOREADER has the potential to dramatically cut these costs by preventing scopes.
"These results are very encouraging for the development of new diagnostic tools for bladder cancer, but we now need to look at larger samples of patients to test the device further before it can be used in hospitals," Probert said.
The study was published in the journal PLOS ONE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 09 2013 | 3:25 PM IST

Next Story